Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | SLC5A8 |
| Gene Name: | SLC5A8 |
| Protein Full Name: | Sodium-coupled monocarboxylate transporter 1 |
| Alias: | Apical iodide transporter;Electrogenic sodium monocarboxylate cotransporter;Sodium iodide-related cotransporter;Solute carrier family 5 member 8 |
| Mass (Da): | 66578 |
| Number AA: | 610 |
| UniProt ID: | Q8N695 |
| Locus ID: | 160728 |
| COSMIC ID: | SLC5A8 |
| Gene location on chromosome: | 12q23.2 |
| Cancer protein type: | TSP |
| Effect of cancer mutation on protein: | LOSS |
| Effect of active protein on cancer: | INHIBITS |
| Number of cancer specimens: | 19626 |
| Percent of cancer specimens with mutations: | 0.92 |
| Gene undergoes hypermethylation: | Down-regulated in some primary cancers; due to aberrant methylation in primary colon cancers, astrocytomas and oligodendrogliomas as well as in cancers of the colon, prostate and gastric regions, and glial cell lines. Expression reactivated on treatment w |
| Normal role description: | SLC5A8 is an electrogenic sodium and chloride-dependent sodium-coupled solute transporter, including transport of monocarboxylates (short-chain fatty acids including L-lactate, D-lactate, pyruvate, acetate, propionate, valerate and butyrate), lactate, mocarboxylate drugs (nicotinate, benzoate, salicylate and 5-aminosalicylate) and ketone bodies (beta-D-hydroxybutyrate, acetoacetate and alpha-ketoisocaproate), with a Na+:substrate stoichiometry of between 4:1 and 2:1. It also catalyzes the passive carrier-mediated diffusion of iodide and its transport from the thyrocyte into the colloid lumen through the apical membrane. It may also be responsible for the absorption of D-lactate and monocarboxylate drugs from the intestinal tract. It acts as a tumour suppressor, suppressing colony formation in colon cancer, prostate cancer and glioma cell lines. It is down-regulated in a number of cancers due to promoter hypermethylation. |
| Commentary on involvement of protein in cancer: | 1/1 (100%) pharyngeal sample was mutated (mis-sense) |